@stacysampen's GLP-1 claims need some fact-checking

What did @stacysampen actually say?

@stacysampen tells her 281K viewers to stop taking semaglutide immediately, claiming there is "no research" on people without type 2 diabetes and that the drug causes kidney failure, gallbladder infection, blindness, cardiac arrest from potassium deficiency, and thyroid tumors. She reads from what she calls the Ozempic website to back herself up, then argues the pharmaceutical industry buries these risks because "it's all about money."

A few of those side effects she listed are real, documented warnings. But the framing around them, the causal mechanisms she invents, and the flat claim that zero research exists outside of diabetic populations are not accurate. That matters, because someone scared by this video might stop a medication that's working for them without talking to a doctor first.

Does the science back this up?

No, not on the key claims. The assertion that there is "literally zero research" on semaglutide in people without type 2 diabetes is flatly wrong. The STEP trial program, published between 2021 and 2022 in the New England Journal of Medicine, enrolled adults with obesity but without diabetes and showed significant weight loss with an acceptable safety profile. Wilding et al. (2021, NEJM) is probably the most cited of these. The FDA approved Wegovy specifically for chronic weight management in adults without diabetes in June 2021.

The side effects she lists, including thyroid C-cell tumors, pancreatitis, diabetic retinopathy complications, and acute kidney injury, do appear in the prescribing information. She is reading real label language. But her explanations of how those side effects work are often invented. Kidney injury is listed as a rare, reported adverse event, not a predictable consequence of the drug's mechanism. Gallbladder disease is not caused by the kidneys failing to "filtrate." These are separate physiological systems.

What did they get wrong (or right)?

She got the list of label warnings roughly right. Reading the prescribing information out loud is not misinformation by itself. Credit where it is due.

But here is where things go sideways. She claims kidney failure leads to gallbladder disease because "your kidneys aren't working so they aren't able to filtrate out everything." That is not how either organ works. The kidneys filter blood. The gallbladder stores bile. Cholelithiasis (gallstones), which is the actual gallbladder risk associated with rapid weight loss, has nothing to do with renal filtration.

Her cardiac arrest explanation is also unsupported. She links cardiovascular death warnings on the label to potassium depletion causing the heart to stop contracting. Semaglutide is not associated with hypokalemia as a primary mechanism. The cardiovascular death language in the prescribing information actually refers to the drug's studied benefit in reducing major adverse cardiovascular events, not a warning that it causes them. She appears to have misread the indication statement as a risk.

• "No research" on non-diabetic populations: inaccurate. Multiple large RCTs exist.
• Thyroid C-cell tumor risk: real label warning, accurate to cite it.
• Kidney injury as a mechanism for gallbladder disease: anatomically incorrect.
• Cardiac arrest from potassium loss: no established pharmacological basis for this claim.
• "You literally have to be on for the rest of your life": contested. Ongoing maintenance dosing is common, but this is a clinical decision, not a pharmaceutical trap.

What should you actually know?

GLP-1 receptor agonists have a real, documented side effect profile. You deserve to know what is actually on the label and what the evidence actually shows, not a distorted version of it.

Thyroid C-cell tumors were observed in rodent studies. The FDA added a black box warning as a precaution. Human epidemiological data have not confirmed this risk translates clinically. Bjerre Knudsen et al. (2010, Regulatory Toxicology and Pharmacology) covered the animal data. Acute pancreatitis is a rare but documented risk. Acute kidney injury events have been reported, typically in the context of severe nausea, vomiting, and dehydration reducing kidney perfusion, not direct nephrotoxicity.

If you are taking semaglutide or tirzepatide for weight management and you saw this video, do not stop your medication based on it. Talk to a licensed clinician who can review your full history. The risks on the label are real risks worth discussing. The mechanisms this creator invented are not.